Paradigm Biopharmaceuticals Ltd (ASX:PAR) has lauded the acceptance of a poster presentation on the company’s phase 2 synovial fluid biomarker clinical trial at the 2023 Osteoarthritis Research Society International (OARSI) World Congress on Osteoarthritis (OA).
The annual OARSI World Congress is the pre-eminent multidisciplinary global forum to showcase and display cutting-edge OA research from academia and industry worldwide.
This global conference will be held in Denver, Colorado, from March 17-20, 2023.
An abstract concerning day 56 results for PAR’s phase 2 trial was submitted under the title 'An exploratory, phase 2 clinical trial in knee osteoarthritis subjects suggests therapeutic effects of pentosan polysulfate sodium on synovial fluid biomarkers of pain, inflammation and chondroprotection', which has been reviewed by the OARSI panel and accepted for a poster presentation over two sessions during the conference.
Paradigm Biopharmaceutical's global clinical head of osteoarthritis Dr Mukesh Ahuja will present the poster and conduct a Q&A throughout the two sessions.
Further validation of iPPS treatment
“To have our exciting data from this phase 2 clinical trial evaluating the disease-modifying potential of injectable pentosan polysulfate sodium (iPPS) selected for presentation at a global OA conference is a fantastic outcome for the company and all Paradigm shareholders,” Paradigm Biopharmaceuticals managing director Paul Rennie said.
“It provides further validation that the data on iPPS treatment in knee OA patients is truly world-class and is being recognised by a global audience of our peers.”
Paradigm will also conduct a sponsored theatre presentation (oral) to OARSI conference attendees covering the company’s OA program, including the day 56 top-line data from the PARA_OA_008 clinical trial and proposed mechanism of action of injectable pentosan polysulfate sodium (iPPS) in osteoarthritis (OA).